<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1685">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04426201</url>
  </required_header>
  <id_info>
    <org_study_id>ILIAD-7 COVID US ONCO</org_study_id>
    <nct_id>NCT04426201</nct_id>
  </id_info>
  <brief_title>InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O )</brief_title>
  <acronym>ILIAD-7-US-O</acronym>
  <official_title>A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection. US Oncology Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Revimmune</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amarex Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Research Institute, New York City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Revimmune</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of the effects of CYT107 vs Placebo administered IM at 10μg/kg twice a week for&#xD;
      three weeks on immune reconstitution of lymphopenic COVID-19 patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately forty-eight (48) participants will be randomized 1:1 to receive&#xD;
&#xD;
      (a) Intramuscular (IM) administration of CYT107 at 10 μg/kg followed, after 72hrs of&#xD;
      observation, by 10 μg/kg twice a week for 3 weeks (maximum 7 administrations adjusted to&#xD;
      patient's length of stay in the hospital) or (b) Intramuscular (IM) placebo (normal saline)&#xD;
      at the same frequency.&#xD;
&#xD;
      The aim of the study is to test the ability of CYT107 to produce an immune reconstitution of&#xD;
      these patients and observe possible association with a clinical improvement.&#xD;
&#xD;
      This cohort is dedicated to oncology patients&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 20, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized controlled of treatment vs placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Unblinded Pharmacist will prepare blinded syringes of colorless drug or placebo</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of the absolute lymphocyte count (ALC) of lymphopenic (ALC≤1000/mm3) COVID-19 infected participants out to approximately 30 days following initial Study drug administration or Hospital discharge (HD), whichever occurs first</measure>
    <time_frame>one month</time_frame>
    <description>A statistically significant increase of the absolute lymphocyte count (ALC) from randomization to day 30 or HospitalDischarge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>&quot;clinical improvement&quot; as defined by a 2 points improvement in a 7-point ordinal scale for Clinical Assessment, through day 30 or HD.</measure>
    <time_frame>one month</time_frame>
    <description>The time to clinical improvement to determine if CYT107 will improve the clinical status of hospitalized COVID-19 patients as measured by clinical improvement score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a significant decline of SARS-CoV-2 viral load through day 30 or HD</measure>
    <time_frame>1 month or HD (whichever occurs first)</time_frame>
    <description>The decrease of SARS-CoV-2 viral load from measurements at baseline and days of treatment dose 4 and dose 5, Day 21 and Day 30 or HD (whichever occurs first)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of secondary infections through day 45 compared to placebo arm</measure>
    <time_frame>45 days</time_frame>
    <description>Incidence of secondary infections based on pre-specified criteria as adjudicated by the Secondary Infections Committee (SIC) through Day 45</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of hospitalization compared to placebo arm</measure>
    <time_frame>45 days</time_frame>
    <description>Number of days of hospitalization during index hospitalization (defined as time from initial Study drug treatment through HD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of stay in ICU compared to placebo arm</measure>
    <time_frame>45 days</time_frame>
    <description>Number of days in ICU during index hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of readmissions to ICU compared to placebo arm</measure>
    <time_frame>45 days</time_frame>
    <description>Readmissions to ICU through Day 45</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>organ support free days compared to placebo arm</measure>
    <time_frame>45 days</time_frame>
    <description>Organ support free days (OSFDs) during index hospitalization (This includes ventilator assistance free days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of re-hospitalization through day 45 compared to placebo arm</measure>
    <time_frame>45 days</time_frame>
    <description>Number of readmissions to the hospital through Day 45</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality through day 45 compared to placebo arm</measure>
    <time_frame>45 days</time_frame>
    <description>All-cause mortality through Day 45</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ and CD8+ T cell counts compared to placebo arm</measure>
    <time_frame>30 days</time_frame>
    <description>Absolute numbers of CD4+ and CD8+ T-cell counts at time points indicated on the Schedule of Activities (SoA) through Day 30 or HD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of other known biomarkers of inflammation: Ferritin compared to placebo arm</measure>
    <time_frame>30 days</time_frame>
    <description>Track and evaluate other known biomarkers of inflammation, Ferritin, from baseline to day 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of other known biomarkers of inflammation: CRP compared to placebo arm</measure>
    <time_frame>30 days</time_frame>
    <description>Track and evaluate other known biomarkers of inflammation, CRP from baseline to day 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of other known biomarkers of inflammation: D-dimer compared to placebo arm</measure>
    <time_frame>30 days</time_frame>
    <description>Track and evaluate other known biomarkers of inflammation, D-dimer from baseline to day 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physiological status through NEWS2 evaluation compared to Placebo arm</measure>
    <time_frame>30 days</time_frame>
    <description>Evaluate improvement of the NEWS2 score value. Score form 0 to 4: NO Risk Score of 7 or more: High risk</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety assessment through incidence and scoring of grade 3-4 adverse events</measure>
    <time_frame>45 days</time_frame>
    <description>Incidence and scoring of all grade 3-4 adverse events through Day 45 (using CTCAE Version 5.0) to assess safety</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>COVID-19</condition>
  <condition>Lymphocytopenia</condition>
  <arm_group>
    <arm_group_label>CYT107 Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular (IM) administration of CYT107 twice a week for 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intramuscular (IM) placebo (normal saline) at the same frequency</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYT107</intervention_name>
    <description>IM administration at 10µg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay</description>
    <arm_group_label>CYT107 Treatment</arm_group_label>
    <other_name>Interleukin-7</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Same number, volume and frequency of IM administration of saline</description>
    <arm_group_label>Saline control</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A written, signed informed consent, or emergency oral consent, by the patient or the&#xD;
             patient's legally authorized representative, and the anticipated ability for&#xD;
             participant to be re-consented in the future for ongoing Study participation&#xD;
&#xD;
          2. Patient receiving active or recent chemotherapy or immunotherapy (within 6 months) for&#xD;
             cancer (and/or)&#xD;
&#xD;
          3. Patients who have received hematopoietic stem cell transplantation (for a diagnosis&#xD;
             other than lymphoma) within the past 1 year (and/or)&#xD;
&#xD;
          4. Patients who received CAR-T cell therapy within the past 1 year (but not within last&#xD;
             30 days- see also exclusion criteria number 6 &amp; 7) (and/or)&#xD;
&#xD;
          5. Patients receiving hormonal therapy for cancer (and/or)&#xD;
&#xD;
          6. Patients who have undergone surgery or radiotherapy for cancer within the past 6&#xD;
             months&#xD;
&#xD;
          7. Men and women aged ≥ 25 - 80 (included) years of age&#xD;
&#xD;
          8. Hospitalized patients with one absolute lymphocyte count (ALC) ≤ 1000 cells/mm3,&#xD;
             collected at baseline or no more than 72h before baseline .&#xD;
&#xD;
             From this time point the investigator may choose to further postpone the commencement&#xD;
             of IL-7 (CYT107) treatment according to patient's clinical status.&#xD;
&#xD;
          9. Hospitalized patients with moderate to severe hypoxemia requiring oxygen therapy at&#xD;
             &gt;4L per minute nasal cannula or greater to keep saturations &gt;90%, non-invasive&#xD;
             positive pressure ventilation (e.g., BIPAP), or patients intubated/ventilated for&#xD;
             respiratory failure&#xD;
&#xD;
         10. Confirmed infection with COVID-19 by any acceptable test available/utilized at each&#xD;
             site&#xD;
&#xD;
         11. Willingness and ability to practice contraception regardless of the gender of the&#xD;
             patient during 5 months after last drug exposure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy or breast feeding;&#xD;
&#xD;
          2. ALT and/or AST &gt; 5 x ULN&#xD;
&#xD;
          3. Known, active auto-immune disease;&#xD;
&#xD;
          4. Patients with a history of lymphoid malignancy&#xD;
&#xD;
          5. Patients with any malignancy that is present at time of enrollment where treating&#xD;
             physician expects life expectancy due to the underlying malignancy to be less than 6&#xD;
             months&#xD;
&#xD;
          6. Patients who received CAR-T cell therapy within the past 30 days or with unresolved&#xD;
             cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity&#xD;
             syndrome (ICANS)&#xD;
&#xD;
          7. Patients with unresolved grade &gt; 2 toxicities from prior chemotherapy, immunotherapy,&#xD;
             or CAR-T cell therapy&#xD;
&#xD;
          8. Patients with past history of Solid Organ transplant.&#xD;
&#xD;
          9. Active tuberculosis, uncontrolled active HBV or HCV infection, HIV with positive viral&#xD;
             load.&#xD;
&#xD;
         10. Hospitalized patients with refractory hypoxia, defined as inability to maintain&#xD;
             saturation &gt;85% with maximal available therapy for &gt;6 hours&#xD;
&#xD;
         11. Patients with a mechanical ventilation support ≥ 7 days&#xD;
&#xD;
         12. Patients with chronic kidney dialysis&#xD;
&#xD;
         13. Patients with a SOFA score ≥ 9 at baseline&#xD;
&#xD;
         14. Patients with a BMI &gt; 40&#xD;
&#xD;
         15. Patients showing an increase of the NEWS2 score by more than 6 points during the&#xD;
             screening/ baseline period (48 to 72 hrs prior to first administration)&#xD;
&#xD;
         16. Patients with hospital admission Rockwood Clinical Frailty Scale ≥ 6. (assessed as&#xD;
             patient or proxy 4-week recall of chronic health and frailty status prior to COVID&#xD;
             infection)&#xD;
&#xD;
        11. Patients under guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Pastores, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcel van den Brink, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michel MORRE, DVM</last_name>
    <phone>+33603357060</phone>
    <email>mmorre@revimmune.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frederique Berbille, MHSc</last_name>
    <phone>+33766459100</phone>
    <email>fberbille@revimmune.com</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. Lancet. 2020 Mar 28;395(10229):1038.</citation>
    <PMID>32171076</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.</citation>
    <PMID>32031570</PMID>
  </results_reference>
  <results_reference>
    <citation>Francois B, Jeannet R, Daix T, Walton AH, Shotwell MS, Unsinger J, Monneret G, Rimmelé T, Blood T, Morre M, Gregoire A, Mayo GA, Blood J, Durum SK, Sherwood ER, Hotchkiss RS. Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. JCI Insight. 2018 Mar 8;3(5). pii: 98960. doi: 10.1172/jci.insight.98960.</citation>
    <PMID>29515037</PMID>
  </results_reference>
  <results_reference>
    <citation>Venet F, Foray AP, Villars-Méchin A, Malcus C, Poitevin-Later F, Lepape A, Monneret G. IL-7 restores lymphocyte functions in septic patients. J Immunol. 2012 Nov 15;189(10):5073-81. doi: 10.4049/jimmunol.1202062. Epub 2012 Oct 10.</citation>
    <PMID>23053510</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 9, 2020</study_first_submitted>
  <study_first_submitted_qc>June 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>December 8, 2020</last_update_submitted>
  <last_update_submitted_qc>December 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphopenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Publication</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

